Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

Gov. Josh Shapiro on Tuesday delivered a $51.5 billion budget proposal for the 2025-2026 fiscal year that he touted as a plan ...

The company's newly restructured I&AF segment, which provides advisory and technical services to various industries, has been ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Recent studies have shed light on these medications’ benefits and potential risks. Ozempic’s common side effects include nausea, diarrhea, constipation, and acid reflux, which are generally mild ...

A recent study from Karolinska Institutet suggests that a type of diabetes medication called GLP-1 agonists could reduce the ...

Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & ...

Obesity significantly impacts cardiovascular health, increasing risks such as left ventricular hypertrophy, atherosclerosis, ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular ...